在ClinicalTrials.gov上报告主方案研究设计的方法:定性分析
该定性分析基于ClinicalTrials.gov注册库,描述了一种报告主方案研究项目(MPRP)的方法。该方法建议在同一主方案下为每个子研究使用单独的注册记录(并注明可能的例外),以清晰、结构化地呈现各子研究预设设计并支持完成后及时报告结果。该方法主要面向ClinicalTrials.gov,但支持推广至其他试验注册库和结果数据库,旨在促进利益相关方讨论、提高对改进MPRP报告必要性的认识并鼓励全球试验注册库的协调统一。
要点
- 提出对主方案研究项目(MPRP)内每个子研究使用单独注册记录的报告方法。
- 该方法旨在清晰、结构化地呈现每个子研究的预设设计并支持完成后及时报告结果。
- 方法主要面向ClinicalTrials.gov,但支持推广至其他试验注册库和结果数据库。
核心结论
- 提出一种适应主方案研究项目(MPRP)复杂设计及其结果的报告方法,即在同一MPRP方案下为每个子研究使用单独的注册记录(并注明可能的例外)。
- 该方法可提供每个子研究预设设计的清晰、描述性、结构化信息,并支持每个子研究完成后及时报告结果。
- 该方法主要面向ClinicalTrials.gov,但支持在试验注册库和结果数据库更广泛地应用,旨在促进利益相关方讨论、提高对改进MPRP报告必要性的认识并鼓励全球试验注册库的协调统一。
研究设计与样本
- 定性分析。
- 数据来源为ClinicalTrials.gov试验注册库。
- 主要结局指标为概述试验报告系统的既定目标及相关实践,审查MPRP的示例和关键特征,并识别在依赖每方案一项研究模型的传统临床试验设计数据库中注册和报告汇总结果的具体挑战。
主要发现
- 提出了一种适应MPRP复杂研究设计及其结果的报告方法。
- 该方法涉及在同一MPRP方案内为每个子研究使用单独的注册记录(并注明可能的例外)。
- 描述了该方法如何提供每个子研究预设设计的清晰、描述性、结构化信息,并支持每个子研究完成后及时报告结果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe an approach for reporting master protocol research programs (MPRPs) that is consistent with existing good reporting practices and that uses structured information to convey the overall master protocol and design of each substudy. DESIGN: Qualitative analysis. DATA SOURCES: ClinicalTrials.gov trial registry. MAIN OUTCOME MEASURES: Established goals and related practices of the trial reporting system were outlined, examples and key characteristics of MPRPs were reviewed, and specific challenges in registering and reporting summary results to databases designed for traditional clinical trial designs that rely on a model of one study per protocol were identified. RESULTS: A reporting approach is proposed that accommodates the complex study design of MPRPs and their results. This approach involves the use of separate registration records for each substudy within one MPRP protocol (with potential exceptions noted). CONCLUSIONS: How the proposed approach allows for clear, descriptive, structured information about each substudy's prespecified design and supports timely reporting of results after completion of each substudy is described and illustrated. Although the focus is on reporting to ClinicalTrials.gov, the approach supports broader application across trial registries and results databases. This paper is intended to stimulate further discussion of this approach among stakeholders, build awareness about the need to improve reporting of MPRPs, and encourage harmonization across trial registries globally.
引用
- Williams RJ, Dobbins HD, Tse T, et al. Approach for reporting master protocol study designs on ClinicalTrials.gov: qualitative analysis. BMJ. 2022. PMID: 35688481. doi:10.1136/bmj-2021-067745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。